NCT00246441View on ClinicalTrials.gov

Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Social Anxiety DisorderSocial PhobiaAlcohol Use DisorderAlcohol AbuseAlcohol Dependence
Interventions
DRUG

Paroxetine

16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day

DRUG

Placebo

treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.

Trial Locations (1)

29425

Medical University of South Carolina, Institute of Psychiatry, Charleston

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Medical University of South Carolina

OTHER

NCT00246441 - Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism | Biotech Hunter | Biotech Hunter